TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

By afschroeder • September 9, 2025

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Mol Ther Oncol. 2025 Aug 14;33(3):201034. doi: 10.1016/j.omton.2025.201034. PMID: 40917508; PMCID: PMC12410479.

Tags: Dermatology, Harbor UCLA, immunotherapy, macrophage reprogramming, myeloid cells, PDAC, Publications, TREM-1 activation

Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical Trial

Armstrong AW, Roberts AM, Kostandy G, Choudhury F, Yee D, Luu M, Jones ME, Alizadeh ER, Cotliar J, Chren MM, Gelfand JM, Cockburn M, Doctor[...]

Alopecia Areata Is Associated with Increased Risk of Infertility in a Retrospective Cohort Study Using TriNetX

Podolsky AS, Goh C, Lipner SR. Alopecia Areata Is Associated with Increased Risk of Infertility in a Retrospective Cohort Study Using TriNetX. Skin Appendage Disord.[...]

Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis

Bchiri S, Bahrini K, Teles RMB, Alaya AB, Kamel HE, West J, Rategh K, Bouzekri A, Bousalem E, Ouni R, Fassatoui M, Mardassi H, Dekhil[...]